Laboratory investigation in the Bleeding Patient. Dr Craig Taylor Consultant Haematologist May 2016

Similar documents
These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides.

Introduction Hemostasis: Tourniquet Test & Bleeding Time. Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO

Special Coagulation - APC Resistance. DiaPharma Group, Inc. Customer Service: Technical Support:

DOAC s and Implications on Laboratory Results. Kandice Kottke-Marchant, MD, PhD Cleveland Clinic

Coagulation Laboratory: Methods, Standards & Cost Effective Testing Part 1

Apheresis Anticoagulant Removal. Oluwatoyosi Onwuemene, MD MS May 6th, 2017

Coagulation in perspective: Blood management. Objectives

R.Li, C.Swaelens, F.Vandermijnsbrugge, B.Cantinieaux BSTH Laboratory of haematology, Porte de Hal,

Basic coagulation applications and case studies

Haemostasis. The function of haemostasis is: to prevent blood loss from injured vessels. to stop bleeding. to prevent thrombosis

SEED Coagulation. Sysmex Educational Enhancement and Development April 2014

2 Thomas G. DeLoughery

Session 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy

Drugs used in Thromboembolic Disease. Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014

Coagulation: The Ins and Outs. Sheila K. Coffman BSMT (ASCP)

Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation

Current laboratory practices in the diagnosis and management of haemophilia

Improving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm

LVHN Scholarly Works. Lehigh Valley Health Network. Joseph G. Ottinger RPh, MS, MBA, BCPS Lehigh Valley Health Network,

Marcia L. Zucker, Ph.D. ZIVD LLC

A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa

Activated Protein C Resistance vs Factor V Leiden assay: Which is the most cost effective?

BLOOD COAGULATION. 1. The initial phase of the process is vascular constriction. This limits the flow of blood to the area of injury.

Common Inherited Bleeding Disorders

PROTHROMBIN TIME WHY USE LOW ISI (HIGH SENSITIVITY)

Evaluation of Unexplained Prolonged APTT &/or PT Review & Update

Customer Service. For further product information, technical advice, prices or to place an order contact. Phone:

Dr Kate Talks, Consultant Haematologist, Newcastle upon Tyne Hospitals NHS Trust Nov 2012

Evaluation of the Bleeding Patient

CHANGE IN PLATELET USAGE

UPDATE ON SPECIFIC ANTIDOTES FOR TARGET-SPECIFIC ORAL ANTICOAGULANTS

Note: The taller 100 x 13 mm tube is not designed to run on the ACL TOP. Plasma after centrifugation of these tubes must be placed in sample cups.

Rheological and biochemical analyses on blood coagulation ~ Discovery of a new pathway under stagnant flow conditions ~

Laboratory Investigation of Challenging Cases. Laura A. Worfolk, Ph.D Scientific Director, Coagulation

With Stago, discover an outstanding Routine range

Massive Haemorrhage J Davies B Ferguson

Why measure thrombin generation? How does measurement of thrombin generation work? Sample material / pre-analytics Test performance Applications

Upon completion of the Clinical Hematology rotation, the MLS student will be able to:

How to Maximize Resources, Optimize Quality and Minimize Costs in the Coagulation Laboratory- by the Laboratory Whisperer

Deep dive into anticoagulant reversal In 20 minutes so we won t dive too deep. Mark Crowther on behalf many Some slides modified from other sources

The Combined Use of Bypassing Agents with Antithrombin Reduction in Plasma of Hemophilia A and B Patients with Inhibitors

Category Storage Shelf Life Additional Criteria

LABORATORY MONITORING OF DIRECT ORAL ANTICOAGULANTS

Disclosures. Thromboelastography. TEG Methodology. TEG Output. Thromboelastography (TEG): Basics & Clinical Applications

Clotting tests. June 2009 V Diagnostica Stago - All right reserved

OERMATAN SULFATE: A NEW CONCEPT IN ANTITHROMBOTIC THERAPY

Anticlotting mechanisms 1: physiology and pathology

Which is the best anticoagulant during primary PCI (p-pci) for STEMI?

Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK

Human Plasmin Activity Assay ELISA Kit

COAGULATION: BASIC PRINCIPLES. Peyman Eshghi Prof. of Pediatric Hematology & Oncology

ASSAY METHODS FOR THE EXPLORATION OF FIBRINOLYSIS

Dr. Suzana Voiculescu

Blood Product Utilization

Analysis of the Anticoagulant Market

Rheological Properties of Fibrin Clots

Please note that the uses described in the following page(s) have not been approved or cleared by FDA, with respect to the described assay or test.

UP AND COMING ANTICOAGULANTS AND HEMOSTASIS AGENTS

ANTICOAGULANT THERAPY ANTICOAGULANT THERAPY REVISITED 2005

Physician Orders - Adult

Information about and Monitoring of Anticoagulant Therapy

Mark Crowther, MD, MSc, FRCPC. Co-authors. Professor of Medicine, McMaster University, Canada

ROTEM/TEG. Circulation in trauma: From roadside to bedside. A/Prof David Roxby SA Pathology Transfusion Service South Australia

Hematotoxin producing snakes in Thailand พญ.ม ชฌ มา รอดเช อ พญ.อ สร ย หาญอ ท ยร ศม

Lovenox weight calculator

ECAT FOUNDATION. External quality Control of diagnostic Assays and Tests with a focus on Thrombosis and Haemostasis

2015 Catalogue Coagulation

BLOOD TRANSFUSION PETER HUDSON CLINICAL SPECIALIST

Overview of Anatomy and Physioloy II Second Year Students

Section 8. To introduce the basic theory and principles of collecting blood for Intraoperative Cell Salvage (ICS)

Activated Partial Thromboplastin Time and Anti-Xa Measurements in Heparin Monitoring. Biochemical Basis for Discordance

Changes in coagulation and tissue plasminogen activator after the treatment of cerebral infarction with lumbrokinase

Marcia L. Zucker, Ph.D. ZIVD LLC

ROTEM Basic Interpretation Guide

REVIEW ARTICLE Thrombin generation and its inhibition: a review of the scienti c basis and mechanism of action of anticoagulant therapies

CLOTTING FACTORS AND COAGULANT BLOOD PRODUCTS

Clinical Policy Guidelines. Management of patients on antithrombotic agents undergoing colonoscopy procedure following positive FOB test.

Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Temporal Aspects.

Comparison of Several Activated Partial Thromboplastin Time Methods

SAMPLE. Determination of Coagulation Factor Activities Using the One-Stage Clotting Assay

Registry for haemophiliacs in France : FranceCoag Network. Thierry Lambert, MD

Stago Newsletter. Diagnostica Stago Pty Ltd 651 Doncaster Road Doncaster, Vic Phone:

CLOTTING FACTOR REPLACEMENT THERAPY

K. Doubleday S. Kumnick. Clot Signature Curves and the ACLAdvance TM

Chapter 19b Blood, cont d

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Anaesthetic considerations in patients with inherited disorders of coagulation

Serine Proteases and their Inhibitors

Laboratory Aspects of recombinant porcine FVIII and extended half life concentrates

Pre-Analytic Issues in Laboratory Medicine

Transcription:

Laboratory investigation in the Bleeding Patient Dr Craig Taylor Consultant Haematologist May 2016

Introduction Bleeding is common May consume significant resources Crossmatched blood Lab results may be missinterpreted There is often an assumption that the cause is the abnormal blood tests May be the other way round Investigation is mostly not in the lab!

Typical Case in EAU 52 year old male Presents to EAU with haematemesis Fresh red blood toilet pan full

What would we like to know from the lab tests? How much has he bled? What volume has he lost Is he still bleeding? Where is he bleeding from? Does he have adequate clotting to stop the bleeding? Is there a bleeding tendency Does he need blood component support?

How much blood has he lost? FBC HB 130 Wbc 12 Plts 430 But how do we interpret this?

Physiological factors Blood loss initially causes loss of circulating volume Volume is replaced initially by protein poor fluid influx And then by albumin containing extracellular fluid Restoration of blood volume after single bleed may take 20-60hrs (or more)

Blood volume and plasma protein changes following haemorrhage (in dogs) T Miller 1944

Change in HCT following bleed (in dogs)

Other factors? When did the bleed start? How long after the bleed is he presenting What was the Hb before the bleed? Have fluids been given? How much? When? Often underestimated?

How much blood loss? Don t know! Clinical picture will be more informative. What if significant anaemia? Same factors need to be considered (esp fluids) Must consider whether this may be a chronic

Look for signs of chronic anaemia Low MCV and MCH? Suggestion of Fe deficiency? Or anaemia of chronic disease High MCV Suggestion of B12/Folate deficiency? Or hypothyroidism? Or haemolysis? Or liver disease? Or alcohol excess?

Is he still bleeding? Serial FBC s? Same factors need to be taken into account Reticulocyte count? Rises after 3-5 days. Peaks at 10 days following bleed.

Is his clotting adequate? Needs to be able to clot to plug the hole! Is there an underlying clotting problem? Has he used them all up? What is it that we need to measure?

Injury IX IXa IX VIIIa TFPI TF/VIIa ATIII (heparin) Plasminogen Activator Inhibitors Plasminogen Activators ( TPA, urokinase) Plasminogen X Prothrombin (II) Antiplasmins (α1 antitrypsin α2 antiplasmin) Xa Va Fibrinogen (I) Plasmin XIa Thrombin (IIa) Fibrin monom er Stable Fibrin XIII XI XIIIa Protein S Protein Ca Protein C = Activates =Inhibits Red = Vitamin K dependant

Clotting tests? INR (or Prothrombin time) Mostly dependent on liver factors Factors II, VII, IX, X Prolonged in liver failure Warfarin therapy Factor VII deficiency DIC/Consumption

APTT Sensitive to deficiencies in the intrinsic pathway Factors XII, XI, X, VII, IX..II Prolonged in: Unfractionated heparin therapy Haemophilia FVIII, FIX deficiency FXII, FXI deficiency Antiphospholipid syndrome Contact factor deficiencies.. DIC/Consumption

Fibrinogen? Cant make a clot without Fibrinogen (Factor 1)! Low in: Congenital deficiency DIC/Consumption But are you being given an actual fibrinogen level?

Derived versus measured Fibrinogen The fibrinogen level can be derived from the rate of formation of the clot in the PT/INR test Produced automatically by anaylsers Rapid and cheap Can also be measured directly using functional assay Clauss fibrinogen More accurate Especially when levels are low

Fibrinogen in the bleeding patient? Laboratory practice will vary Clauss for all? Screen with derived? Clauss should be used if level may be low Ie. May need to replace Which result are you getting?

What about other anticoagulants? LMWH Act mostly on FXa Have no or little effect on routine clotting results Can assay anti-xa activity not in emergency NOACS/DOACS May not affect routine clotting at therapeutic levels May get varying results with different reagents

Dabigatran (direct thrombin inhibitor) May affect the INR/APTT Normal results may suggest a low level Normal TT excludes residual effect Rivaroxaban (direct Xa inhibitor) May affect the INR/APTT (not TT) May have prophylactic levels with normal results BUT Only in labs where the sensitivity of their reagents has been confirmed

Interpreting Patient results (1) INR 10 APTT 1.5 Fibrinogen 4.5 Disproportionate rise in INR Almost certainly on warfarin

Interpreting patient results (2) INR 1.0 APTT 2.1 Fib 3.8 Isolated prolongation of APTT Is he on unfractionated heparin? Is he a haemophiliac? Does he have acquired haemophilia? Does he have anti-phospholipid syndrome? Does he have a clinically irrelevant factor deficiency

Interpreting patient results (3) INR 2.0 APTT 1.8 Fibrinogen 1.2 Suggests consumption/dic

Does Renal failure contribute? End stage renal disease May have platelet dysfunction Due to uraemic toxins Dialysis patients Often use heparin New onset renal dysfunction Are they on LMWH or a DOAC? These are renal excreted May be supratherapeutic

Conclusions/Take home messages Need to understand what question is being asked of the lab tests Hb may be a poor indicator of blood loss Clotting is a complex process Lab tests are imperfect Effects of DOACS are hard to measure, and reagent dependent